WilmerHale Counsels Special Committee of Emisphere Technologies in $1.8B Acquisition by Novo Nordisk

Download IconDownload Print IconPrint

WilmerHale Counsels Special Committee of Emisphere Technologies in $1.8B Acquisition by Novo Nordisk

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
On November 6, Emisphere Technologies, Inc. announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a deal valued at $1.8 billion. Novo Nordisk will acquire Emisphere for $1.35 billion in cash. At the same time, Novo Nordisk has also entered into an agreement to acquire the related royalty stream obligations owed to affiliates of MHR Fund Management LLC for $450 million.

The Board of Directors of Emisphere approved the merger upon the unanimous recommendation of a Special Committee consisting entirely of independent and disinterested Emisphere directors. The deal is subject to customary closing conditions.

The WilmerHale team representing the Special Committee includes Hal Leibowitz and Joseph Conahan.

Read the full press release.  
 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel